Given the substantial stores of endogenous GLP-1, pharmacological mobilization of these reserves holds a potential promise as an alternative to current GLP-1R based treatment strategies for type 2 diabetes and obesity, and may potentially prove to be more efficacious than GLP-1R mono-therapy, since it would be accompanied by co-secretion of other anorectic hormone products of the L-cell. The gene discussed is GLP1R; the disease is obesity disorder.